Eurofins Reinforces Its Leading Footprint in Food Testing in France with the Acquisition of Agro-Analyses
2016年6月1日 - 2:30PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in bioanalytical
testing to support the entire food production chain, announces the
acquisition of Agro-Analyses SAS (“Agro-Analyses”), one of the
leading analytical service providers supporting the food retail and
catering sectors in France.
Founded nearly 30 years ago, Agro-Analyses employs 157 staff at
its site in Metz, in the northeast of France. The company provides
food safety testing with a strong competence in microbiology, as
well as surface analysis, for its clients primarily in the food
retail and catering sectors, and generates annual revenues in
excess of EUR 10m.
This acquisition further strengthens Eurofins’ leadership in the
French food testing market, especially in the area of food quality
and safety assessment. Agro-Analyses’ strong footprint in the east
of the country is a good fit with Eurofins’ leading western
franchise. Furthermore, the acquisition should allow the Group to
accelerate the deployment of its unparalleled capabilities in
microbiology, as well as the rest of its competencies nationwide,
and to a broader client base. In return, Agro-Analyses will benefit
from Eurofins’ industry-leading laboratory network, including
access to the Group’s comprehensive analytical portfolio, as well
as logistical infrastructure.
Comment from Dr. Gilles Martin, Eurofins CEO: "The acquisition
of Agro-Analyses further consolidates our leading footprint to
support the entire food industry in France. We look forward to
giving Agro-Analyses’ clients full access to the capabilities of
the Eurofins network to support them in further strengthening and
optimizing their quality assurance programs.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific believes it is the world leader in food,
environment and pharmaceutical products testing, as well as one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160531006215/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2024 まで 8 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 8 2023 まで 8 2024